Innovations in CTO

Disclosure(s):

Emmanouil S. Brilakis, MD, PhD: Abbott Cardiovascular Systems: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Biotronik: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); boston scientific: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Cleerly Health: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Cordis: Consulting Fees (e.g., advisory boards) (Ongoing); Elsevier Publishing: royalties (Ongoing); GE Healthcare: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Haemonetics: Consulting Fees (e.g., advisory boards) (Ongoing); Hippocrates LLC: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); IMDS: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); MHI Ventures: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Stallion Medical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing); Teleflex: Consulting Fees (e.g., advisory boards) (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); TrueVue Inc: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (Ongoing)